The effects of l-alanine supplementation in late-onset glycogen storage disease type II
- PMID: 10980742
- DOI: 10.1212/wnl.55.5.710
The effects of l-alanine supplementation in late-onset glycogen storage disease type II
Abstract
Myopathy in glycogen storage disease type II (GSD-II) is slowly progressive. Five subjects with the late-onset form of GSD-II (age range, 15 to 47 years) and seven healthy control subjects (age range, 28 to 55 years) were studied. Following alanine supplementation, resting energy expenditure decreased in patients with GSD-II (p < 0.05) compared to values seen in control subjects. Leucine flux decreased (p < 0.004), as did leucine oxidation, to levels lower than those observed in control subjects (p < 0.001). l-Alanine reduces protein turnover and catabolism in GSD-II.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources